YUTREPIA™ (treprostinil) inhalation powder
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Liquidia
Liquidia's mission is to develop best-in-class therapies for rare cardiopulmonary diseases, helping patients breathe easier and live longer. The company has successfully transitioned from a technology platform to a commercial entity with the FDA approval and launch of YUTREPIA™ for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its strategy centers on maximizing the commercial potential of YUTREPIA™, advancing its pipeline through clinical development, and exploiting the versatility of its PRINT® platform for future inhaled therapeutics.
View full company profileAbout Liquidia
Liquidia's mission is to develop best-in-class therapies for rare cardiopulmonary diseases, helping patients breathe easier and live longer. The company has successfully transitioned from a technology platform to a commercial entity with the FDA approval and launch of YUTREPIA™ for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its strategy centers on maximizing the commercial potential of YUTREPIA™, advancing its pipeline through clinical development, and exploiting the versatility of its PRINT® platform for future inhaled therapeutics.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| LIQ861 (treprostinil) inhalation powder | Liquidia | Phase 3 |
| L606 (liposomal treprostinil) injection | Liquidia | Preclinical |
| NTP42 | ATXA Therapeutics | Phase 1 |